GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-10-25|

FDA Accepts NMP's Clinical Trial Application for Development of NMK89 as Imaging Agent for Cancer Diagnosis

by GeneOnline
Share To

 – Clinical Study Set to Begin, Focusing on Diagnostic Use of Theranostics –

TOKYO, Oct. 25, 2022 /PRNewswire/ — Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company in Japan, is pleased to announce that the U.S. Food and Drug Administration (FDA) has recently accepted NMP’s Investigational New Drug (IND) application to initiate a first-in-human phase I clinical study of "NMK89 (development code)," which is an imaging agent currently developed for cancer diagnostic use in cancer theranostics (a fusion of therapeutics and diagnostics) (*1). The clinical study can now be started.

NMK89 is an RI (*2)-labeled humanized anti-MUC5AC (*3) antibody to which zirconium-89, a diagnostic radionuclide, is labeled and has been investigated in non-clinical studies conducted by NMP and Sumitomo Pharma Co., Ltd. as an imaging agent for the diagnosis of MUC5AC-expressing cancer. It has been reported that MUC5AC is highly expressed in pancreatic cancer, liver cancer, colon cancer, gastric cancer, and lung cancer, among others. Non-clinical studies have confirmed that NMK89 accumulates in tumors transplanted with cell lines expressing MUC5AC.

NMP is developing NMK89 in one of the research projects (*4) adopted by the Japan Agency for Medical Research and Development (AMED) to enable early commercialization of theranostics for use in nuclear medicine.

NMP is conducting the phase I study of NMK89 in the U.S. NMP will promptly begin clinical studies of therapeutic drugs by leveraging the data on NMK89, obtained from the phase I study, to swiftly materialize it as long-awaited theranostics.

Notes:
(*1) It is a therapeutic concept in which RI-imaging diagnostics is used in advance to determine whether the drug reaches the target protein in the patient and to provide treatment with the radionuclide modified for therapeutic use. This enables therapies that are more closely aligned with a diagnosis and is expected to contribute to personalized medicine and the effective utilization of medical costs.

(*2) Radioisotopes – Radiation they emit is used for cancer treatment and diagnosis.

(*3) Mucin subtype 5AC – A type of mucin which is the main component of mucus secreted by animal epithelial cells. It is generally expressed in normal tissues of the stomach and trachea but is also reported to be highly expressed in pancreatic cancer and several other cancers.

(*4) The research project known as "Development of Antibody Labeling Therapies (with Alpha-Particle) and Companion Diagnostics, in Parallel with Maintenance of Drug Research Facilities to Embody the Concept of Theranostics" was adopted by AMED’s "Cyclic Innovation for Clinical Empowerment (CiCLE)" – FY2017 (2nd Conference).

About Nihon Medi-Physics Co., Ltd.
Nihon Medi-Physics is engaging in ensuring stable supply and research and development of new products as a leading manufacturer of radiopharmaceuticals in Japan. Based on the technological proficiency and trust built over the years, the company is also working on research and development of "theranostics (a combination of therapeutics and diagnostics)," which is a novel medical technology to provide optimal medical service to each patient, as well as on the dissemination of nuclear medicine in Asian countries by licensing its products. The company will continue contributing to society by creating values as a life science company.
Official website: https://www.nmp.co.jp/eng/index.html

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
2025-01-10
United Imaging Announces Major Expansion of U.S. Manufacturing Space
2025-01-09
Complete Genomics announces mpox virus amplicon sequencing panel at AMP
2024-11-20
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top